Financing led by Frazier Life Sciences with participation from new investors EQT Life Sciences, Forbion, Monograph, Wellington Management and founding investor LifeArc Ventures
- Proceeds support clinical development of lead programme RQB01 designed to provide seasonal influenza protection with a single administration
- Christian S. Schade appointed Executive Chairman
Naarden, The Netherlands, 24 June, 2026 - Forbion, a leading global life sciences venture capital firm with deep roots in Europe, announces its participation in RQ Bio’s oversubscribed $115 million (£85.5 million) Series A financing to support the advancement of RQB01, a long-acting antibody programme designed for full-season influenza prevention.
Financing was led by Frazier Life Sciences with participation from new investors EQT Life Sciences, Forbion, Monograph, Wellington Management and founding investor LifeArc Ventures, alongside Oxford Science Enterprises and the University of Oxford.
The proceeds will support the clinical development of RQB01, which is currently in IND-enabling studies and is designed to provide seasonal influenza protection through a single administration.
RQ Bio’s approach to influenza prevention combines advanced antibody engineering with the expertise of a highly experienced team, creating the potential to address a significant unmet need for immunocompromised patients. We are delighted to support the company alongside our outstanding syndicate partners as it advances RQB01 into the clinic and works to establish a best-in-class, long-acting option for influenza prophylaxis."
Jon Edwards, PhD
General Partner, Forbion
"Influenza remains a serious and persistent threat for patients whose immune systems cannot rely on vaccination alone," said Mike Westby, Chief Executive Officer of RQ Bio. "Our vision is to develop a preventative therapy capable of delivering reliable protection for an entire flu season with a single administration. This financing will support clinical development of RQB01 as well as advance our proprietary antibody discovery approach towards a pipeline of assets for prophylaxis of respiratory viral diseases.”
Read the RQ Biotechnology company release here.
About RQ Bio
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The Company is advancing its lead product RQB01, a long-acting, potent and broadly protective antibody product, through IND-enabling studies.
Founded in 2021, RQ Bio has a highly experienced team with proven success in developing long-acting antibodies against viral targets. RQ Bio is backed by a strong syndicate of investors – Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, and LifeArc Ventures as well as Oxford Science Enterprises and the University of Oxford.
About Forbion
Forbion is a leading global venture capital firm with deep roots in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 10 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.
